A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer  by Pant, Shubham et al.
European Journal of Cancer 56 (2016) 1e9Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.ejcancer .comOriginal ResearchA first-in-human phase I study of the oral Notch
inhibitor, LY900009, in patients with advanced cancerShubham Pant a,c, Suzanne F. Jones c, Carla D. Kurkjian a,c,
Jeffrey R. Infante b,c, Kathleen N. Moore a,c, Howard A. Burris b,c,
Donald S. McMeekin a,c, Karim A. Benhadji d, Bharvin K.R. Patel d,
Martin J. Frenzel d, Jonathan D. Kursar d, Maciej J. Zamek-Gliszczynski d,
Eunice S.M. Yuen e, Edward M. Chan d, Johanna C. Bendell b,c,*a Stephenson Cancer Center University of Oklahoma, Oklahoma City, OK, USA
b Tennessee Oncology, Nashville, TN, USA
c Sarah Cannon Research Institute, Nashville, TN, USA
d Eli Lilly and Company, Indianapolis, IN, USA
e Eli Lilly and Company, Windlesham, Surrey, UKReceived 6 May 2015; received in revised form 2 October 2015; accepted 23 November 2015




LY900009* Corresponding author: Sarah Canno
4125; fax: þ1 (615) 524-4625.
E-mail address: jbendell@tnonc.com
http://dx.doi.org/10.1016/j.ejca.2015.11.0
0959-8049/ª 2015 The Authors. Pub
creativecommons.org/licenses/by-nc-nd/Abstract Background: Notch signalling regulates stem cell development and survival and is
deregulated in multiple malignancies. LY900009 is a small molecule inhibitor of Notch signal-
ling via selective inhibition of the g-secretase protein. We report the first-in-human phase I
trial of LY900009.
Methods: Dose escalation (Part A) was performed in cohorts of three advanced cancer pa-
tients using a modified continual reassessment method and dose confirmation (Part B) was
performed in ovarian cancer patients. LY900009 was taken orally thrice weekly (every
Monday, Wednesday, and Friday) during a 28-d cycle. The primary objective determined
the maximum tolerated dose (MTD); secondary end-points included toxicity, pharmacoki-
netics, pharmacodynamics, and antitumour activity.
Results: Thirty-five patients received LY900009 at dose levels ranging from 2e60 mg. Study
drug-related adverse events were diarrhoea (46%), vomiting (34%), anorexia (31%), nausea
(31%), and fatigue (23%). At 30 mg, a dose-limiting toxicity (grade III mucosal inflammation)
was observed. LY900009 absorption was rapid, with median tmax at 1e4 h post-dose.
LY900009 inhibited plasma levels of amyloid-b peptide in a dose-dependent manner with
80e90% inhibition observed in the 30- to 60-mg cohorts. No responses were seen, but fiven Research Institute, 3322 West End Avenue, Suite 900, Nashville, TN 37203, USA. Tel.: þ1 (615) 524
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S. Pant et al. / European Journal of Cancer 56 (2016) 1e92patients had stable disease. Two patients (5.7%) with leiomyosarcoma and ovarian cancer
received four cycles of therapy. One patient (15 mg) showed markedly increased glandular
mucin consistent with pharmacologic inhibition of the Notch pathway.
Conclusions: The recommended MTD schedule for future studies was 30 mg thrice weekly,
which exceeds the target inhibition level observed in preclinical models to promote tumour
regression in humans.
ª 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The Notch signalling pathway is involved in stem cell
development and maintenance, both key components of
cancer cell survival and metastasis [1,2]. Notch signal-
ling regulates expression of receptor tyrosine kinases,
including the pro-angiogenic vascular endothelial
growth factor receptor-1 [3] and the pro-growth
epidermal growth factor receptor [4,5]. Also, Notch
signalling is a component of stem cell fate and differ-
entiation in a variety of tissues [6].
Notch cell surface receptors 1e4 are heterodimeric
proteins composed of extracellular and intracellular
domains [7]. The extracellular domain contains
conserved epidermal growth factor-like repeat domains
involved in ligand binding [7]. Notch is activated by its
ligands, which are Delta/Serrate/lag-2 (DSL) proteins in
Drosophila (Delta-like and Jagged proteins in verte-
brates). Upon activation, the Notch receptor undergoes
proteolytic cleavages that release the Notch intracellular
domain (NICD) which translocates to the nucleus and
functions as a transcriptional regulator. The NICD in-
teracts with a CBF-1/RBPjk/Su(H)/Lag-1 (CSL) protein
which binds DNA and directs NICD to target genes.
This complex recruits transcriptional coactivator
MasterMind/Lag-3 and regulates protein expression
involved in proliferation, differentiation, and apoptosis
[8].
Aberrant expression of Notch signalling components
correlates with breast cancer growth, metastasis, and
poor prognosis [1,9e11]. Evidence suggests that
deregulated Notch 1e4 signalling is also implicated in
numerous malignancies [7,9,10,12]. In serous ovarian
cancer, Notch signalling pathway is altered in 22% of
cases [12]. Notch3 overexpression in ovarian cancer cells
also results in expansion of cancer stem cells and
increased platinum chemoresistance [13]. Therefore, in-
hibition of Notch signalling via g-secretase may be an
attractive cancer therapy target.
LY900009, a selective inhibitor of the g-secretase
protein, inhibits cleavage of NICD. LY900009 inhibited
Notch signalling in tumour cell lines and endothelial
cells (half maximal inhibitory concentration [IC50]
range: 0.005e20 nM) [14]. In a xenograft tumour model,
LY900009 dose dependently inhibited Notch cleavageand induced apoptosis 24 h after a single 3 mg/kg oral
dose. Animal tumours treated with LY900009 also
revealed inhibition of angiogenesis through formation of
leaky vasculature, which may possibly contribute to
antitumour activity. Furthermore, LY900009 produced
tumour regression in Notch-dependent tumour models
[15].
Here, we report the first-in-human phase I trial of
LY900009 designed to evaluate the safety and tolera-
bility of LY900009. Secondary objectives included
pharmacokinetics (PK), pharmacodynamics (PD), pre-
liminary antitumour activity, and establishing a recom-
mended dose of LY900009.
2. Patients and methods
2.1. Study objectives
The primary objective was to evaluate the safety and
tolerability of LY900009 when administered orally to
patients with advanced cancer. The secondary objectives
were to determine the PK of LY900009, evaluate PD
and predictive biomarkers, establish a recommended
dose range of LY900009 in the absence of corticosteroid
therapy, and explore antitumour activity of LY90009.
2.2. Patient eligibility
Eligible patients (18 years) had disease refractory to
standard therapy (or no available standard therapy)
and a 12-week expectancy. In Part A (dose escala-
tion), patients had non-measurable or measurable
advanced and/or metastatic solid tumour or lym-
phoma. In Part B (dose confirmation), patients had
measurable advanced or metastatic ovarian cancer.
Measurable disease was defined by Response Evalua-
tion Criteria in Solid Tumours (RECIST) v1.1 [16] or
the Revised Response Criteria for Malignant Lym-
phoma [17]. Patients discontinued all treatments up to
21 d prior to enrolment, except for patients with breast
or prostate cancers progressing on endocrine therapies
who may have continued treatment. Patients had a
performance status of 1 (Part A) and 2 (Part B) on
the Eastern Cooperative Oncology Group scale.
Adequate haematopoietic, renal, and hepatic functions
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approved drugs within 21 d, serious preexisting medi-
cal conditions, and females who were pregnant or
lactating.
2.3. Study design
This was a multi-centre, dose escalation phase I study of
LY900009 (Eli Lilly and Company, Indianapolis, IN) in
patients with advanced and/or metastatic cancer. The
established dosing regimen was based on non-clinical
toxicity and PK/PD data. During dose escalation (nZ 35
planned), LY900009 was administered orally thrice
weekly (Monday, Wednesday, and Friday [MWF]) on a
28-d cycle. Dose escalationwas performed usingmodified
continual reassessment methods (CRMs) previously
described [18e25]. Briefly, a set of predefined criteria
included prespecified dose levels (2, 4, 8, 15, 30, 60, 90,
and 120 mg), a maximum tolerated dose (MTD) defined
as the highest dose with probability of dose-limiting
toxicity (DLT) 33%, cohort sizes (n Z 3), maximum
dose level escalation of one increment (no restrictions on
dose de-escalation), and a stopping rule defined as either
six patients (two cohorts) treated at a dose level in which
the CRM recommends the same dose levels again or if the
prespecified maximum number of subjects (e.g. 36) is
reached. ThemodifiedCRMalso assumed a logistic dose-
toxicity model that incorporated the probability of a
DLT event and the transformed dose.
After identifying the MTD in Part A, eight patients
with ovarian cancer were enrolled in the tumour-specific
cohort expansion as this tumour type is associated with
Notch gene amplification. During Part B, patients were
treated at a dose less than or equal to MTD. A thorough
investigation of DLT-equivalent toxicities occurring in
>33% of patients was performed before continuing
therapy.
2.4. Safety
Safety was monitored using Common Terminology
Criteria for Adverse Events Version 4.02 (CTCAE
v4.02). DLTs possibly related to LY900009 occurring
during cycle 1 met these criteria: grade III or higher
neutropenia with fever, grade III or higher thrombocy-
topaenia with bleeding; grade IV haematological
toxicity persisting >5 d; grade III or higher nausea,
vomiting, or electrolyte disturbance persisting >2 d; and
grade III or higher non-haematological toxicity except
grade 3 nausea/vomiting/electrolyte disturbance. A
DLT-equivalent toxicity occurred between day 1 and 28
of any cycle (other than cycle 1) for patients enrolled in
Part A or in any cycle (including cycle 1) for patients
enrolled in Part B who would have met DLT criteria for
DLT if it had occurred during cycle 1 for patients
enrolled in Part A.2.5. PK studies
Serial plasma samples were collected on days 1 and 22
(cycle 1) and a predose sample on day 1 (cycle 2) for PK
evaluation. Plasma concentrations of LY900009 and its
active tertiary alcohol metabolite (LSN2831047) were
determined using a validated liquid chromatography/
tandem mass spectrometry (LC/MS/MS) assay. PK
parameters were calculated using non-compartmental
analyses following single and multiple doses of
LY900009.
2.6. Exploratory metabolism and excretion studies
In Part B, PK plasma (days 1 and 22 [cycle 1]) and
urine (0e24 h collection on day 1) samples were
collected. Samples were pooled and profiled for me-
tabolites using positive-ion electrospray ionisation
mass spectrometry. Urine concentrations of LY900009
and LSN2831047 were quantified by a validated LC/
MS/MS assay.
2.7. PD studies
PD analyses were performed on plasma samples
collected on days 7 and 21 (cycle 1). Blood samples were
collected for exploratory analysis of circulating amyloid-
b peptides using a validated enzyme-linked immuno-
sorbent assay system.
2.8. Antitumour activity
Tumours were measured by computerised tomography
scan, magnetic resonance imaging, and/or chest X-ray
and assessed using RECIST [26].
2.9. Statistical analyses
All analyses were descriptive and reported by dose and
for all patients combined wherever appropriate.
3. Results
3.1. Patient disposition
Thirty-five patients (Part A, n Z 27; Part B, n Z 8)
received more than one dose of LY900009, of which all
patients completed cycle 1. Of the 27 patients enrolled in
Part A, patients received LY900009 2 mg (nZ 3), 4 mg
(n Z 4), 8 mg (n Z 3), 15 mg (n Z 3), 30 mg (n Z 6),
45 mg (n Z 5), or 60 mg (n Z 3). All eight patients
enrolled in Part B received 30 mg LY900009. All pa-
tients received prior anticancer treatment. Baseline pa-
tient and disease characteristics are summarised in
Table 1.
Table 1
Baseline patient and disease characteristics
Characteristics Patients
Part Aa (N Z 27) Part Bb (N Z 8)
Sex, n (%)
Male 8 (29.6) 0




Ethnic origin, n (%)
Caucasian 25 (92.6) 7 (87.5)
African-American 2 (7.4) 0
Missing 0 1 (12.5)
ECOG performance status, n (%)
0 22 (81.5) 6 (75)
1 5 (18.5) 2 (25)
Tumour type, n (%)
Colon/rectum 5 (18.5) 0
Endometrium 3 (11.1) 0
Ovary 3 (11.1) 8 (100)
Pancreas 3 (11.1) 0
Sarcoma 2 (7.4) 0
Lung (NSCLC) 2 (7.4) 0
Other 9 (33.3) 0
Prior therapy, n (%)
Systemic therapy 27 (100) 8 (100)
Surgery 26 (96.3) 8 (100)
Radiotherapy 13 (48.1) 1 (12.5)
Abbreviations: ECOG, Eastern Cooperative Oncology Group;
NSCLC, non-small-cell lung cancer.
a Part A, dose escalation.
b Part B, dose confirmation.
S. Pant et al. / European Journal of Cancer 56 (2016) 1e943.2. Safety
In dose escalation (Part A), 27 patients received more
than one dose of LY900009 (Table 2). The median
number of cycles completed was 2.0 (range: 1e4 cycles).
The mean study dose intensity was 56.4%. In Part A,
two patients (nZ 1 in the 2 mg and 30 mg cohorts) with
leiomyosarcoma and ovarian cancer completed four
treatment cycles. Dose escalation proceeded asTable 2








1 2 mg 3 0
2 4 mg 4 0
3 8 mg 3 0
4 15 mg 3 0
5 30 mg 6 0 Established as MTD
6 60 mg 3 2 Gr III fatigue, nausea, and
vomiting (n Z 1); Gr III
diarrhoea (n Z 1)
7 45 mg 5 2 Gr III fatigue, nausea, and
vomiting (n Z 1); Gr III
diarrhoea (n Z 1)
Abbreviations: DLT, dose-limiting toxicity; Gr, grade; MTD,
maximum tolerated dose; MWF, Monday, Wednesday, and Friday.described. A total of four patients experienced eight
DLTs during cycle 1; all occurred during Part A. At the
60-mg dose level, two of three patients experienced
DLTs: one patient experienced fatigue, nausea, and
vomiting (all grade III) and another diarrhoea (grade
III). At an intermediate dose level of 45 mg, two of five
patients experienced the same DLTs as those reported
for 60-mg dose level. Therefore, the 30-mg dose level
was established as the MTD for LY900009.
In dose confirmation (Part B), eight patients with
ovarian cancer received more than one dose of
LY900009. The median number of cycles completed was
1.0 (range: 1e2 cycles). The mean study dose intensity
was 47.9%. Two of three patients experienced study
drug-related serious adverse events (SAEs) (one patient
experienced grade III vomiting and dehydration and the
other grade III fatigue). One patient experienced a DLT-
equivalent toxicity as previously defined (grade III
mucosal inflammation) possibly related to treatment
(30 mg dose) and later discontinued due to the DLT. At
the MTD, six patients (75%) experienced a treatment-
emergent AE (TEAE), with common AEs being diar-
rhoea, anorexia, nausea, and vomiting.
Of all patients dosed in Part A (n Z 27) and Part B
(n Z 8), respectively, the primary reason for discontin-
uation of the study drug was due to progressive disease
(51.9% and 37.5%). Discontinuation due to AEs was
11.4% and deaths 9.5%. The TEAEs for which four
patients discontinued treatment included grade III
diarrhoea (45 mg dose), grade III mucosal inflammation
(30 mg dose), grade II nausea (30 mg dose), and grade II
fatigue (30 mg dose). No other patients experienced
grade II toxicities that led to dose interruptions. All AEs
were study drug related, except for grade II fatigue, but
none were considered an SAE as determined by the
investigator. The diarrhoea and mucosal inflammation
events were considered DLTs. Four patients who
received more than one dose of LY900009 died within
30 d of their last dose. Three patients were in Part A
(n Z 2 at 2 mg dose and n Z 1 at 60 mg dose) and one
patient in Part B (30 mg dose). All deaths were due to
progressive disease and not study drug related.
Among the 35 patients who received more than one
dose of LY900009, the most frequent treatment-related
TEAEs (all grades) included diarrhoea (45.7%), vomit-
ing (34.3%), anorexia (31.4%), nausea (31.4%), and fa-
tigue (22.9%, Table 3). The most common grade III
TEAEs were diarrhoea (11.4%), vomiting (8.6%), fa-
tigue (8.6%), and hypophosphatemia (8.6%). There were
no TEAEs grade IV or higher possibly related to
treatment (Table 3).
3.3. Pharmacokinetics
PK data (n Z 35 [day 1 post-single dose] and n Z 16
[day 22 post-multiple dosing]) are reported in Table 4.
LY900009 absorption was rapid (median tmax
Table 3
Treatment-emergent adverse events possibly related to treatment (all gradesa that occurred in 10% of patients)
Adverse event Part A (N Z 27) Part B (N Z 8) Parts A þ B (N Z 35)
All grades, n (%) Grade (n) All grades, n (%) Grade (n) All grades, n (%)
1 2 3b 1 2 3b
Diarrhoea 10 (37) 3 4 3 6 (75) 2 3 1 16 (46)
Vomiting 8 (30) 3 3 2 4 (50) 3 0 1 12 (34)
Anorexia 7 (26) 3 4 0 4 (50) 2 1 1 11 (31)
Nausea 8 (30) 2 4 2 3 (38) 1 2 0 11 (31)
Fatigue 6 (22) 2 2 2 2 (25) 0 1 1 8 (23)
Rash acneiform 5 (19) 4 1 0 0 0 0 0 5 (14)
Oral mucositis 3 (11) 3 0 0 2 (25) 1 0 1 5 (14)
Hypophosphatemia 4 (15) 0 1 3 0 0 0 0 4 (11)
a Grades are according Common Terminology Criteria for Adverse Events, version 4.02.
b There were no treatment-emergent adverse events grade IV or higher possibly related to treatment.
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half-life ranged from 2 to 4 h across doses. The linearity
index, the ratio of area under the concentration time
curve, AUC(t,ss), after multiple dosing to AUC(0eN)
after a single dose, was w1, suggesting that LY900009
PK did not change with time. Geometric percent coef-
ficient of variation was 50e80% at doses >15 mg. In an
exploratory assessment of dose proportionality, no
major departures from linearity were noted.
Apparent conversion of LY900009 to its metabolite,
LSN2831047, was fairly rapid (median tmax approxi-
mately 2e6 h post-dose, Table 4). The metabolite t1/2
was longer than the parent (range: 5e14 h), suggesting
that the metabolite is elimination rate limited. As
demonstrated by the metabolite:parent (M:P) ratio in
Table 4, metabolite exposures were approximately 4e9
times higher than parent LY900009.Table 4
Noncompartmental analysis of LY900009 and LSN2831047 PK parameter
LY90000
Cohort 2 mg 4 mg 8 mg
N 3c 4 3
Cmax (ng/ml) 4.03 (122) 11.7 (70) 20.2 (68)
tmax
a (h) 3.00 (1.00e5.98) 1.02 (0.50e2.77) 1.00 (1.00e1.33)
t1/2
b (h) (1.84e2.34) 2.00 (1.46e3.39) 2.36 (1.89e2.90)
AUC(0eN) (ng h/ml) (8.37e35.6) 31.6 (48) 76.2 (123)
CL/F (l/h) (56.2e239) 127 (48) 105 (124)
Vss/F (l) 181e1250 460 (62) 420 (103)
LSN28310
tmax
a (h) 5.98 (3.08e6.05) 1.90 (0.50e6.48) 3.00 (1.33e3.00)
t1/2
b (h) 7.78 (4.57e12.1) 6.65 (5.45e7.83) 4.89 (1.67e11.3)
AUC(0eN) (ng h/ml) 116 (35) 290 (25) 511 (64)
M:P (ratio) (4.62e10.3)d 9.17 (31) 6.71 (47)
Abbreviations: AUC0eN, area under the concentration time curve from
observed concentration; CV, coefficient of variation; M, metabolite; MTD
tients; P, parent; t1/2, elimination half-life; tmax, time to Cmax; Vss/F, volum
a Median (range).
b Geometric mean (range).
c NZ2 for all parameters, except for Cmax and tmax. One patient was exclu
d Represents M:P (range).3.4. Metabolism and excretion
Six LY900009 metabolites were observed in plasma and
urine. LY900009 was primarily metabolised by oxida-
tion to a tertiary alcohol (LSN2831047) and amide hy-
drolysis. LSN2831047 exhibited 1/9 of the in vitro
potency of parent LY900009 for inhibition of Notch
cleavage. Accumulation of the tertiary metabolite of the
amide hydrolysis pathway after multiple dosing (day 1
versus 22) was observed.
Recovery of parent LY900009 in urine was low
(mean  standard deviation, 1.3  0.8% of oral dose),
supporting metabolic clearance. LSN2831047 accounted
for 10.0  1.9% of the LY900009 oral dose in urine.
Renal clearance of both LY900009 and LSN2831047
was consistent with the unbound glomerular filtration
rate.s following a single dose of LY900009
9: Geometric mean (CV%)
15 mg 30 mg (MTD) 45 mg 60 mg
3 14 5 3
27.4 (50) 71.2 (104) 96.2 (37) 158 (35)
3.00 (1.00e3.00) 1.06 (0.50e3.12) 3.00 (1.00e6.22) 4.00 (0.50e6.03)
2.18 (1.82e2.99) 2.37 (1.30e4.09) 2.68 (2.24e3.21) 3.99 (2.69e8.20)
121 (59) 351 (71) 547 (32) 1240 (53)
123 (59) 95.2 (71) 82.2 (32) 48.5 (53)
593 (63) 419 (98) 461 (54) 344 (46)
47: Geometric mean (CV%)
3.00 (3.00e3.00) 3.10 (3.00e6.07) 6.00 (3.00e6.22) 4.00 (3.00e6.03)
7.76 (6.45e10.6) 8.40 (4.57e15.6) 8.37 (6.59e10.9) 13.8 (6.81e36.5)
1020 (25) 2100 (40) 2310 (35) 4820 (56)
8.38 (35) 6.66 (59) 4.23 (26) 3.9 (9)
0 to infinity; CL/F, apparent total body clearance; Cmax, maximum
, maximum tolerated dose; PK, pharmacokinetics; N, number of pa-
e of distribution at steady state.
ded due to insufficient quantifiable concentrations in terminal phase.
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Figure 1 shows the ratio of circulating amyloid-b to
baseline after LY900009 dosing. Generally, maximal
decreases of 80e90% in amyloid-b plasma levels were
achieved at doses 30e60 mg, both after single and
multiple dosing.
Inhibition of Notch signalling by LY900009 was
further observed in the gastrointestinal tract (Fig. 2).
LY900009 (15 mg) induced goblet cell differentiationFig. 1. Ratio to baseline of amyloid-b by dosage group. The ratio to bas
single (A) and multiple (B) doses of LY900009.and increased glandular mucin production in the
gastrointestinal tract, similar to the observation in rats.
3.6. Antitumour activity
Of the 35 enrolled patients, 21 patients were radiologi-
cally assessed for tumour response while on study. No
patients exhibited a complete or partial response. Five
patients (14%) from Part A exhibited stable disease
(SD). The tumour types and duration of treatmenteline (R2B) of amyloid-b (total plasma [pg/ml]) was measured after
Fig. 2. Evidence of inhibition of Notch signalling by immunohistochemical analysis. The effect of LY900009 on the gastrointestinal tract in a
rat model (top panels) compared with a patient sample assigned to the 15 mg cohort (bottom panel).
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cinoma (106 d), non-small-cell lung carcinoma (73 d),
ureter carcinoma (57 d), rectal carcinoma (55 d), and
leiomyosarcoma (113 d).
4. Discussion
This is the first-in-human trial of the g-secretase inhib-
itor LY900009 in patients with advanced cancer. Pa-
tients were dosed thrice weekly, a regimen derived from
preclinical toxicology studies where gastroenteropathy
was more pronounced on daily dosing [14].
Most patients (75%) experienced low-grade, study
drug-related TEAEs during the study. Grade III
possibly study drug-related CTCAEs were reported in
eight patients (29.6%) in Part A and four patients (50%)
in Part B. No study drug-related grade IV CTCAEs
were reported. Diarrhoea, vomiting, anorexia, and
nausea were common study drug-related TEAEs. DLTs
occurred in patients at LY900009 doses 30 mg. An
MTD of 30 mg every MWF was established. A high
percentage (75%) of study drug-related TEAEs and one
dose reduction (cycle 2 and dose 1) was observed at the
MTD. Improving LY900009 tolerability at the MTD
such that long-term tolerability (beyond two cycles) can
be achieved may be beneficial.
Efficacy was not the primary objective for this study
and a relatively small cohort of patients received treat-
ment at the MTD. Limited antitumour activity was
observed, with no complete or partial responses and
14% of patients achieving SD. In general, minimal
clinical activity as single-agent has been noted in g-sec-
retase inhibitor trials [12]. Furthermore, g-secretase in-
hibitor monotherapy is associated with gastrointestinal
toxicities [12], particularly with continuous dosing
schedules [27], which may limit the ability to achieve
optimal exposure times. g-Secretase inhibitor therapycombined with chemotherapy [28] and glucocorticoids
[29] may be more effective in preventing tumour growth
and progression while limiting unwanted toxicity mon-
otherapy [30,31]. For instance, glucocorticoid treatment
protects against g-secretase inhibitor-induced intestinal
toxicity in mice [32]. Despite an improved safety profile
with g-secretase combined therapy, immune system
function may be affected [29]. Another oral g-secretase
inhibitor combined with gemcitabine using intermittent
dosing in patients with advanced cancer demonstrated a
favourable safety profile, similar to monotherapy [33]
and LY900009. These studies suggest that appropriate
dosing may minimise systemic toxicity.
LY900009 absorption was rapid (median tmax
approximately 1e4 h post-dose). With an MWF dosing
scheme, it is unlikely that significant accumulation of
both the parent and metabolite occurred, as evidenced
by similar exposures after single and multiple dosing.
LY900009 was cleared primarily by metabolism via
oxidation to an active tertiary alcohol (LSN2831047)
and amide hydrolysis, consistent with semagacestat, a
structurally similar g-secretase inhibitor; however, un-
like semagacestat, renal clearance of LY900009 was low
[34].
LY900009 produced similar antitumour activity
when administered thrice weekly compared with daily
dosing in preclinical experiments [35,36]. Based on me-
dian predicted human PK parameters and non-clinical
models [35,36], a median LY900009 dose of 20 mg
administered orally thrice weekly every 28 d was pre-
dicted to produce the required level of target inhibition
(30e50% of Notch1 inhibition) needed to observe
tumour regression in humans. PD markers are also
valuable in target inhibition validation since conven-
tional MTDs may yield unnecessary toxicity [37]. As
previously mentioned, protease g-secretase cleaves am-
yloid precursor protein which releases the amyloid-b
S. Pant et al. / European Journal of Cancer 56 (2016) 1e98peptide [38]. Amyloid-b may be a suitable surrogate PD
marker of Notch signalling following administration of
g-secretase inhibitors [39e41]. Here, we report marked
decreases in plasma amyloid-b levels (up to 90%), which
were sustained up to 48 h post-LY900009 doses ranging
from 30 to 60 mg. Although amyloid-b demonstrates
evidence of PD effect in plasma, further studies are
needed to investigate Notch inhibition in tumour tissues
as well as explore whether alterations in the Notch
pathway may predict clinical outcome.
In summary, g-secretase inhibitor LY900009 has a
manageable safety profile with tolerability limited pri-
marily by gastrointestinal effects. The drug demon-
strates acceptable PK and PD effect in patients with
advanced cancer. While supportive evidence demon-
strated cellular differentiation and potential disease
control among patients using monotherapy, further
clinical efficacy may be achieved with combination
therapy. Future studies should explore LY900009 on an
intermittent schedule combined with either chemo-
therapy or targeted agents to achieve greater clinical
efficacy.
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